AIM ImmunoTech (AIM) Other Working Capital Changes (2010 - 2026)
AIM ImmunoTech's (AIM) quarterly Other Working Capital Changes came in at -$70000.0 in Q1 2026, down 12.9% YoY from -$80370.4 in Q1 2025, and up 47.76% on a QoQ basis from -$134000.0 in Q4 2025.
AIM ImmunoTech (AIM) Other Working Capital Changes (2010 - 2026) Analysis & Trends
AIM ImmunoTech (AIM) has 7 years of Other Working Capital Changes data on file, last reported at -$70000.0 in Q1 2026.
- Quarterly Other Working Capital Changes fell 12.9% year-over-year to -$70000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$276000.0 (up 35.96% YoY) and the FY2025 annual result came in at -$268000.0, up 13.27% from the prior year.
- Other Working Capital Changes improved to -$70000.0 in Q1 2026, from -$134000.0 in the prior quarter.
- In the past five years, Other Working Capital Changes ranged from a high of $678000.0 in Q4 2023 to a low of -$702000.0 in Q4 2025.
- A 5-year average of -$42588.2 and a median of -$8000.0 in 2022 frame the typical range for Other Working Capital Changes.
- Annual changes were most pronounced in 2022 — Other Working Capital Changes surged 6872.73% — and 2024, when it slumped 1800.0%.
- Tracing AIM's Other Working Capital Changes over 5 years: stood at -$29000.0 in 2022, then slumped by 375.86% to -$138000.0 in 2023, then soared by 43.48% to -$78000.0 in 2024, then sank by 71.79% to -$134000.0 in 2025, then jumped by 47.76% to -$70000.0 in 2026.
- The last three Other Working Capital Changes figures came in at -$70000.0 (Q1 2026), -$134000.0 (Q4 2025), and -$56000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.59 Bn | 131.73 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 86.21 Bn | 78.22 Bn | 3.93 Bn |
| 3 | Argenx Se | 65.65 Bn | 60.47 Bn | 1.37 Bn |
| 4 | Moderna | 57.67 Bn | 52.53 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 42.10 Bn | 37.00 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.62 Bn | 28.31 Bn | 992.69 Mn |
| 7 | BioNTech SE | 27.90 Bn | 9.51 Bn | 668.28 Mn |
| 8 | Insmed | 27.51 Bn | 26.35 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.29 Bn | 26.45 Bn | - |
| 10 | AIM ImmunoTech | 4.42 Mn | -5.54 Mn | 21,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 27,000.00 |
| Jun 30, 2026 | 27,000.00 |
| Jun 30, 2026 | 27,000.00 |
| Mar 31, 2026 | -50,000.00 |
| Mar 31, 2026 | -50,000.00 |
| Mar 31, 2026 | -50,000.00 |
| Dec 31, 2025 | -702,000.00 |
| Dec 31, 2025 | -702,000.00 |
| Dec 31, 2025 | -702,000.00 |
| Sep 30, 2025 | -24,000.00 |
| Sep 30, 2025 | -24,000.00 |
| Sep 30, 2025 | -24,000.00 |
| Jun 30, 2025 | 358,000.00 |
| Jun 30, 2025 | 358,000.00 |
| Jun 30, 2025 | 358,000.00 |
| Mar 31, 2025 | -367,000.00 |
| Mar 31, 2025 | -367,000.00 |
| Mar 31, 2025 | -367,000.00 |
| Dec 31, 2024 | -639,000.00 |
| Dec 31, 2024 | -639,000.00 |